"Low-Dose"-Methotrexate-Therapy in Rheumatoid Arthritis - An Update;"Low-Dose"-Methotrexat-Therapie bei chronischer Polyarthritis - Ein Update

Acta Medica Austriaca

Volumn 23, Issue 4, 1996, Pages 114-119

  Leeb, B F ^a,c   Smolen, J S ^b  

^a Zentrum F Diagnose Therapie R   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Long term therapy; Methotrexate; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DYSPNEA; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; PANCYTOPENIA; REVIEW; RHEUMATOID ARTHRITIS; VASCULITIS; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; LONG TERM CARE; METABOLIC CLEARANCE RATE; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONG-TERM CARE; METABOLIC CLEARANCE RATE; METHOTREXATE; TREATMENT OUTCOME;

EID: 0030331659     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Alarcon GS, Tracy IC, Blackburn WD jr.: Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthr Rheum 1989;32:671-676.
2. Balis FM, Mirro J, Reaman GH, Evans WE, McCully C, Doherty KM, Murphy RF, Jeffries S, Poplack DG: Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-1886.
3. Bannwarth B, Labat L, Moride Y, Schaeverbeke T: Methotrexate in rheumatoid arthritis. An update. Drugs 1994;47:25-50.
4. Beyeler C, Jordi B, Gerber NJ, Im Hof V: Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: A longitudinal study. Br J Rheumatol 1996;35:446-452.
5. Blackburn WD, Alarcon GS: Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthr Rheum 1989;32:1341-1342.
6. Bologna C, Viu P, Jorgensen C, Sany J: Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996;35:453-457.
7. Cronstein BN, Eberle MA, Gruber HE: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:241-245.
8. Edelman J, Biggs DF, Jamali F, Russel AS: Low-dose methotrexate kinetics in arthritis. Clin Rharmacol Ther 1984;35:382-386.
9. Firestein GS, Pine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis, selective decrease in synovial collagenase gene expression. Arthr Rheum 1994;37:193-200.
10. Furst DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheum 1995;34 (Suppl. 2):20-25.
11. Furst DE, Herman RA, Koehnke R et al.: Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-786.
12. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-320.
13. Galivan J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980;17:105-110.
14. Gubner R, August S, Ginsberg V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-182.
15. Haagsma CJ, van Riel PLCM, van der Putte LBA: Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Br J Rheumatol 1995;34 (Suppl. 2):104-108.
16. Hamdy H, McKendry RJR, Mierins E, Liver JA: low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthr Rheum 1987;30:361-367.
17. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE: Pharmacokinetics of low-dose Methotrexate in rheumatoid arthritis patients. Pharm Sci 1989;78:165-171.
18. Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ: Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996;35:441-445.
19. Hoffmeister RT: Methotrexate in rheumatoid arthritis. Arthr Rheum 1972;15 (Suppl.):114.
20. Huffman DH, Wan SH, Azarnoff DL, Hoogstraten B: Pharmacokinetics of Methotrexate Clin Pharmacol Ther 1973;14:572-579.
21. Janknegt R, Nube NJ, van den Hoogenzand F, Oldenhof HGW, Steenhoek A, Vree TB: Pharmacokinetics of methotrexate in continuos ambulatory peritoneal dialysis. Pharmaceut Weekblad 1988;10:86-89.
22. Kingsmore SF, Hall BD, Alen NB, Rice JR, Caldwell DS: Association of methotrexate, rheumatoid arthritis and lymphoma: Report of two cases and literature review. J Rheumatol 1992;19:1462-1465
23. Kremer JM: Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Br J Rheumatol 1995;34 (Suppl. 2):26-29.
24. Kremer JM, Alarcon GS, Lightfood RW jr: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthr Rheum 1994;37:316-328.
25. Kremer JM, Galivan J, Streckfuss A, Kamen B: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthr Rheum 1986;29:832-835.
26. Kremer JM, Lee JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthr Rheum 1986;29:822-831.
27. Kremer JM, Petrillo GF, Lawrence DH: Methotrexate induces significant changes in IL-1, IL-2, IL-6 and 1L-8 but not lymphocyte markers in patients with rheumatoid arthritis. Arthr Rheum 1993;36:77.
28. Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthr Rheum 1992;35:138-145.
29. Leeb B, Dunky A, Ogris E, Mutzik O: Pharmacokinetics of methotrexate in rheumatoid and psoriatic arthritis. Arthr Rheum 1990;33 (Suppl. 9):A 121 (Abstr.).
30. Leeb B, Dunky A, Ogris E, Wohanka A, Schenk G, Fischer M, Tausch G, Eberl R:. Hämatozelluläres Methotrexate bei Langzeittherapie entzündlich rheumatischer Erkrankungen. Acta med Austr. 1988;15:140-144.
31. Leeb B, Dunky A, Ogris E, Wohanka A, Schenk G, Gaismayer K, Eberl R: Methotrexate serum-level determinations during low-dose therapy of rheumatoid and psoriatic arthritis. Int J Clin Pharm Res 1989;IX(3):209-215.
32. Leeb BF: Should folate supplementation be routinely recommended for older patients receiving methotrexate? Drugs & Aging 1994;5:319-322.
33. Leeb BF, Studnicka-Benke A, Steiner G, Smolen JS: Methotrexate therapy is associated with a reduction of TNF-alpha and soluble TNF-receptor levels in serum of patients with psoriatic arthritis but not with rheumatoid arthritis. Arthr Rheum 1993;36 (Suppl. 9):248 (Abstr.).
34. Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, Smolen JS: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-463.
35. May KP, West SG, McDermott MT, Huffer WE: The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthr Rheum 1994;37:201-206.
36. Morgan SL, Baggot JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthr Rheum 1990;33:9-18.
37. Nuernberg B, Koehnke R, Solsky M, Hoffman J, Furst DE: Biliary elimination of low-dose methotrexate in humans Arthr Rheum 1990;33:898-902.
38. O'Dell JR, Haire CE, RN, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-1291.
39. Oguey D, Kölliker F, Gerber NJ, Reichen J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis Arthr Rheum 1992;35:611-614.
40. Pinkerton CR, Glasgow JFT, Welshman SG, Bridges JM: Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 1980;2:944-945.
41. Roenigk IIH Jr, Auerbach R, Maibach HI: Methotrexate guidelines - revised. J Am Acad Derm 1982;6:145-155.
42. Sandoval DM, Alarcon GS, Morgan SL: Adverse events in methotrexate treated rheumatoid arthritis patients. Br J Rheumatol 1995;34 (Suppl. 2):49-56.
43. Segal R, Yaron M, Tartakowsky B: Methotrexate: Mechanism of action in rheumatoid arthritis. Sem Arthr Rheum 1990;20 (3):190-199.
44. Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C: Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthr Rheum 1994;37:830-833.
45. Siegmeth W, Eberl R, Tausch G, Raith W: Vergleichende Untersuchung der Wirkung des Antimetabolikums Methotrexate bei Psoriasis, Arthropathia psoriatica und Rheumatoider Arthritis. Verh Dtsch Ges Rheumatol 1969;1:383-387.
46. Sinette MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS jr: Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheum 1989;16:745-748.
47. Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinhlatt ME: Acute and chronic suppression of leukotrien B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthr Rheum 1992;35:376-384.
48. Stewart KA, Mackenzie AH, Clough JD, Wilke WS: Folate supplementation in methotrexate treated rheumatoid arthritis patients. Semin Arthr Rheum 1991;20:332-338.
49. Suarez-Alamor ME, Fitzgerald A, Grace M, Russel AS: A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol 1988;15:753-756.
50. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE: Methotrexate bioavailability after oral and intramuscular administration in children J Pediatr 1987;110:788-792.
51. Tishler M, Caspi D, Fishel B, Yaron M: The effect of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthr Rheum 1988;31:906-908.
52. Thomas R, Carrol GJ: Reduction of leukocyte and Interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthr Rheum 1993;36:1244-1252.
53. Tugwell P, Bennett K, Gent M: Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy and safety. Ann Int Med 1987;107:358-366.
54. Walker AM, Funch D, Dreyer NA: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthr Rheum 1993;36:329-335.
55. Weinblatt ME: Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995;34 (Suppl. 2):43-48.
56. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822.
57. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, Torretti D, Weissmann B: Methotrexate in rheumatoid arthritis. A five year prospective multicenter study. Arthr Rheum 1994;37:1492-1498.
58. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Irby R, Wolfe F, Gall E, Torretti D, Biundo J, Small R, Coblyn J, Polisson R: Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double blind trial. Arthr Rheum 1990;33:330-338.
59. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, Weissmann B: The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthr Rheum 1993;36:613-619.
60. Weinstein GD, Frost P: Methotrexate for Psoriasis. Arch Derm 1971;103:33-38.
61. Wilkens RF, Sharp JT, Stablein D, Marks C, Wortmann R: Comparison of azathioprine, methotrexate and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthr Rheum 1995;38:1799-1806.
62. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14 year prospective study. J Rheumatol 1990;17:994-1002.
63. Zachariae H, Kragballe K, Thestrup-Pederscn K, Kissmeyer-Nilsen F: HLA-antigens in methotrexate-induced liver cirrhosis. Acta Derm Venerol 1980;60:165-166.